(Q33347522)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

Martin J van den Bent

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

F E de Jongh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R N van Veen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

S J Veltman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R de Wit

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M E L van der Burg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A S Th Planting

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

W J Graveland

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

G Stoter

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J Verweij

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

language of work or name

English

0 references

publication date

1 April 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1199-1206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule.

2 November 2019

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Oxidant stress in the vasculature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Increased nephrotoxicity of combination taxol and cisplatin chemotherapy in gynecologic cancers as compared to cisplatin alone

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Risk factors for ototoxicity due to cisplatin.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Weekly high-dose cisplatin in malignant pleural mesothelioma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Ototoxicity of low- and moderate-dose cisplatin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

21 June 2018

Cisplatin neurotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

High-dose cisplatin treatment: hearing loss and plasma concentrations.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Sequences of taxol and cisplatin: a phase I and pharmacologic study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2747572

Cisplatin-lnduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity

31 October 2018

1 reference

12 December 2020

Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline

1 reference

12 December 2020

Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration

1 reference

12 December 2020

Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat

1 reference

12 December 2020

High-Dose Cisplatin in Hypertonic Saline

1 reference

12 December 2020

Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients

1 reference

12 December 2020

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

1 reference

12 December 2020

Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo

1 reference

12 December 2020

The relative nephrotoxicity of cisplatin,cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600884

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 November 2019

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12698184%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

PubMed publication ID

12698184

1 reference